International Journal of Chemical Science
www.chemicaljournals.com
Online ISSN: 2523-2843, Print ISSN: 2523-6075
Received: 21-10-2025, Accepted: 20-11-2025, Published: 05-12-2025
Volume 9, Issue 2, 2025, Page No. 79-84

Heterocyclic Carboxamides: A strategic review on the Anticancer Potential of Tetrazole and Triazole motifs in drug discovery

Sushil Eknathrao Jamale, Dr Suresh Govardhan Vedpatahk
Department of Chemistry, S M D. Mohekar Mahavidyalya kalamb, Dharashiv, Maharashtra, India

Abstract
The enduring challenge of cancer and the rise of drug resistance necessitate the continuous discovery of novel, selective therapeutic agents. This review critically assesses the crucial role of heterocyclic carboxamide scaffolds, focusing specifically on the fusion of the carboxamide functional group with the nitrogen-rich tetrazole and triazole motifs, in contemporary anticancer drug development. The carboxamide group is highlighted as a versatile pharmacophore providing essential hydrogen-bonding and conformational control. The review details how the tetrazole ring acts as a potent carboxylic acid bioisostere in targeted agents like VEGFR-2 kinase inhibitors, while the 1,2,3-triazole ring, predominantly formed through high-yielding Click Chemistry, serves as a rigid, metabolically stable linker in compounds targeting HDACs and tubulin polymerization. Key structure-activity relationships (SAR) are summarized, organized by biological mechanism. Furthermore, we discuss the advanced methodologies—including High-Throughput Screening (HTS) and computational modeling (3D-QSAR)—that are accelerating compound optimization and target validation. Finally, we address persistent challenges such as poor bioavailability and off-target toxicity, concluding that integrating sophisticated computational design with synthetic flexibility will be essential for translating these potent preclinical hits into clinically viable therapeutics.

Keywords: Heterocyclic carboxamide, tetrazole, triazole, anticancer drugs, kinase inhibitors

Introduction

Cancer remains a formidable global public health crisis and a leading cause of mortality worldwide [1]. Despite tremendous advances in diagnosis and treatment—including surgery, radiotherapy, and targeted therapies—the disease continues to challenge medicine due to its remarkable complexity, high incidence of drug resistance, and significant associated toxicity from current therapeutic agents [2]. This evolutionary pressure of cancer demands the continuous and accelerated discovery of novel chemotherapeutic agents with improved selectivity and potency [3].

In the ongoing quest for new therapeutic agents, heterocyclic compounds are arguably the most indispensable chemical frameworks in medicinal chemistry. These ring structures, containing at least one atom other than carbon, are ubiquitous in nature and synthetically derived drugs, constituting the core of approximately 80% of all FDA-approved small-molecule pharmaceuticals [4]. The strategic inclusion of heterocyclic rings is critical because they bestow essential physicochemical properties—such as optimal pKa values, enhanced solubility, and favorable membrane permeability—that are necessary for achieving ideal drug-like properties and superior pharmacokinetics [5].

Coupled with these rings, the carboxamide ($CONR_2$) functional group stands out as a critical pharmacophore [6]. The carboxamide is highly valued for its geometric stability and its ability to participate in crucial binding interactions within biological targets. Specifically, the group acts as a potent hydrogen-bond donor and acceptor, frequently serving as a key linker or conformational constraint in targeted inhibitors, exemplified by famous kinase inhibitors like Imatinib and Sorafenib [7].

This review focuses specifically on advanced hybrid scaffolds combining the crucial carboxamide group with two particularly important nitrogen-rich heterocycles: the tetrazole and triazole rings [8]. The combined chemical and biological appeal of these heterocyclic carboxamide hybrids lies in their capacity to act as bioisosteres (e.g., tetrazole mimicking the carboxylic acid moiety), serve as versatile, metabolically stable linkers (e.g., triazole from click chemistry), and significantly improve binding affinity for critical cancer targets [9, 10].

Therefore, this article critically reviews the recent advances in the design, synthesis, and biological evaluation of novel tetrazole and triazole carboxamide scaffolds as promising candidates in anticancer drug discovery. The specific objective is to analyze the crucial Structure-Activity Relationships (SARs) and the diverse synthetic utility and biological activities through which these scaffolds exert their anticancer effects, thereby highlighting their potential for future therapeutic development.

Tetrazole-Carboxamide Hybrids as Anticancer Agents

The strategic incorporation of the 1H-tetrazole ring N_4CH into a carboxamide scaffold has proven highly fruitful in anticancer drug discovery. The tetrazole ring is chemically and metabolically stable and serves as a highly effective bioisostere for the carboxylic acid (COOH) moiety [9]. Its slightly acidic nature (pKa ≈ 4.9) and ability to form strong chelating interactions make it ideal for interacting with the active sites of metalloenzymes and key signaling proteins. This section classifies the most significant anticancer activities of tetrazole-carboxamide hybrids based on their proposed biological targets.

1. Tetrazole Carboxamides as Kinase Inhibitors

Protein kinases are crucial regulators of cell proliferation, differentiation, and survival, making them prime targets in oncology. Tetrazole-carboxamide hybrids frequently act as effective kinase inhibitors by targeting the ATP-binding pocket.

For instance, several novel derivatives have been reported to inhibit the Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) and Platelet-Derived Growth Factor Receptor (PDGF) [11]. The tetrazole group in these molecules often coordinates with specific residues or provides a crucial H-bond interaction within the active site, mimicking the carboxylic acid in naturally occurring ligands.

Key Observations

- **Tetrazole position:** The attachment point of the tetrazole relative to the carboxamide linker significantly impacts potency.
- **Substituents:** Optimal activity often requires electron-withdrawing groups (e.g., F, Cl, CF_3) on the aromatic rings attached to the carboxamide nitrogen.

2. Inhibitors of Topoisomerase Enzymes

Topoisomerases (Topo) are essential enzymes that regulate DNA topology, and their inhibition is a classic strategy for chemotherapy. Tetrazole-carboxamide structures have emerged as potent Topo-I and Topo-II inhibitors, functioning by stabilizing the cleavable complex and leading to fatal DNA double-strand breaks [12]. The planar nature of the heterocyclic rings facilitates the necessary intercalation into the DNA structure, while the carboxamide provides key stabilization for the drug-enzyme-DNA ternary complex.

3. Dual COX-2/LOX Inhibitors and Cytotoxicity

Beyond direct DNA or protein targeting, some tetrazole-carboxamide hybrids exhibit anti-inflammatory mechanisms that are highly relevant to cancer progression, particularly through the inhibition of cyclooxygenases (COX) and lipoxygenases (LOX) [13]. COX-2 is often overexpressed in tumors and promotes angiogenesis and cell survival. Tetrazole bioisosterism helps these compounds fit into the active site of COX-2, and by modulating COX and LOX activity simultaneously, they can suppress tumor growth and metastasis.

Key SAR Observations

- The size and lipophilicity of substituents around the tetrazole ring are critical for achieving dual COX-2/LOX selectivity.
- The presence of a diaryl framework linked by the carboxamide is a common feature in this class.

Table 1: Representative Tetrazole-Carboxamide Anticancer Agents and SAR Summary

Compound Scaffold (Ref.)	Biological Target/Mechanism	IC50 (μM) Range	Key SAR Highlights
Tetrazole-N-aryl-carboxamide [11]	VEGFR-2 Kinase Inhibition	0.05 – 0.5	Phenyl ring substitution with Cl or F at the para position enhanced potency 5-fold.
Tetrazole-Carboxamide Fused Ring [12]	Topoisomerase I	1.2 – 4.5 (against HepG2)	Extended fused aromatic systems enhanced DNA intercalation and toxicity.
Diaryl-Tetrazole-Carboxamide [13]	Dual COX−2/LOX Inhibition	COX−2: 0.1 – 0.9	Small alkyl groups on the carboxamide nitrogen improved selectivity over COX−1.
Novel Tetrazole-Containing Hybrid [14]	Tubulin Polymerization	0.01 – 0.1	The tetrazole ring acted as an optimal linker for a trimethoxyphenyl motif.

Triazole-Carboxamide Hybrids as Anticancer Agents

The 1,2,3-triazole ring is another prevalent nitrogen heterocycle in medicinal chemistry, highly favored for its stability, polarity, and robust synthetic accessibility. Unlike the tetrazole, which often serves as a bioisostere, the 1,2,3-triazole typically functions as a metabolically stable, rigid linker in drug candidates [10]. Its incorporation into the carboxamide scaffold creates powerful molecular hybrids, many of which are synthesized using the highly efficient copper(I)-catalyzed alkyne-azide cycloaddition (CuAAC), universally known as Click Chemistry [15]. This section details the anticancer activities of triazole-carboxamide hybrids, highlighting the contribution of Click Chemistry.

Click Chemistry and Scaffold Assembly

Click Chemistry provides a nearly perfect and regioselective route to the 1,2,3-triazole ring. This efficiency allows researchers to quickly synthesize large libraries of triazole-carboxamide hybrids by combining diverse azide and alkyne components, a process essential for effective Structure-Activity Relationship (SAR) studies [16]. Many highly active triazole-carboxamide anticancer agents owe their discovery to this rapid construction method, enabling the swift conjugation of known pharmacophores to the carboxamide unit.

Triazole Carboxamides as Kinase and HDAC Inhibitors

Similar to their tetrazole counterparts, triazole-carboxamide hybrids show significant activity against various kinase targets, including EGFR and Src kinases. The triazole ring and the neighboring carboxamide group together form a critical binding motif that can precisely orient the inhibitor within the enzyme's binding pocket [17].

Beyond kinases, this scaffold is notably effective as an inhibitor of Histone Deacetylases (HDACs), which are epigenetic targets frequently overexpressed in cancer. In HDAC inhibitors, the triazole-carboxamide moiety can act as a zinc-binding group or, more commonly, as a stable linker connecting the cap (which interacts with the enzyme surface) and the metal-chelating group [16].

Key SAR Observations

- **Linker function:** The rigidity and H-bonding capacity of the 1,2,3-triazole ring stabilize the overall conformation, which is crucial for HDAC active-site occupancy.
- **Substituent size:** The nature and size of the substituents on the triazole ring significantly modulate potency, likely by optimizing van der Waals interactions with the kinase or HDAC domain.

1. Tubulin Polymerization Inhibitors

A large number of triazole-carboxamide compounds exhibit potent cytotoxicity by targeting the tubulin/microtubule system [18]. These molecules interfere with the polymerization or depolymerization of tubulin, disrupting

mitotic spindle formation and arresting cells in the G2/M phase, leading to apoptosis. The triazole group often facilitates the optimal geometrical alignment required for effective binding at the colchicine-binding site on tubulin, with the carboxamide providing critical hydrogen bonding.

Table 2: Representative Triazole-Carboxamide Anticancer Agents and SAR Summary

Compound Scaffold (Ref.)	Biological Target/Mechanism	IC50 (μM) Range	Key SAR Highlights
1,2,3-Triazole-Carboxamide [17]	EGFR Kinase Inhibition	0.08 – 0.4	Compounds derived from Click Chemistry showed superior yield and purity; p-OMe substituents on the aromatic ring improved metabolic stability.
Triazole-Carboxamide-Hydroxamate [16]	HDAC Inhibitor	0.2 – 1.5	Triazole served as a rigid spacer; the length of the alkyl chain linker critically determined potency.
Triazole-Carboxamide-Benzene [18]	Tubulin Polymerization	0.02 – 0.25 (against A549)	N-aryl substitution on the carboxamide linked to a 1,2,3-triazole ring led to potent cytotoxic effects, mimicking the structure of known antitubulin agents.

Synthetic Strategies and Challenges

The development of tetrazole and triazole carboxamide hybrids relies on robust and efficient synthetic methodologies that allow for rapid library generation for SAR studies. The synthetic approach for each heterocycle differs significantly, leveraging the unique reactivity of their precursors.

1. Strategies for Triazole-Carboxamide Scaffolds

The primary synthetic route for constructing 1,2,3-triazole carboxamides is the venerable Copper(I)-Catalyzed Alkyne-Azide Cycloaddition (CuAAC), a cornerstone of Click Chemistry [15].

- **CuAAC (Click Chemistry):** This reaction involves coupling an alkyne with an azide in the presence of a copper(I) catalyst, yielding the 1,4-disubstituted 1,2,3-triazole product with high efficiency, excellent regioselectivity, and under mild conditions. In the context of your review:
- The carboxamide group is typically integrated into either the alkyne or the azide precursor.
- This strategy is highly desirable as it minimizes unwanted by-products, simplifies purification, and allows for the quick creation of diverse molecular conjugates, crucial for connecting the carboxamide and triazole to different pharmacophore units.

2. Strategies for Tetrazole-Carboxamide Scaffolds

The synthesis of tetrazole carboxamides often involves methods to introduce the four nitrogen atoms sequentially or via cyclization of readily available precursors.

- **Cycloaddition of Nitriles:** The most common and direct method involves the reaction of a nitrile (RCN) precursor—where the carboxamide unit is already incorporated into the Rgroup—with an azide source (typically NaN_3) under high pressure or elevated temperature, often catalyzed by metal salts like $ZnBr_2$ or organotin compounds [9]. This forms the 5-substituted tetrazole ring.

- **Coupling Reactions:** Alternatively, a pre-formed 5-substituted tetrazole can be coupled with an amine using standard peptide-coupling reagents (e.g., EDC\HOBt or DCC) to form the carboxamide linkage, especially if the tetrazole is intended to mimic a carboxylic acid.

3. Key Synthetic Challenges

Despite the advancements, challenges remain in scaling up these syntheses:

1. **Azide Handling:** The use of organic azides and sodium azide, particularly in large scale, requires careful handling due to their potential instability and toxicity.

2. **Copper Contamination:** Trace amounts of copper catalyst from the CuAAC reaction must be rigorously removed, as copper can interfere with subsequent biological assays.

3. **Regioselectivity:** While CuAAC is highly regioselective, alternative tetrazole synthesis routes can sometimes yield 1H- and 2H-tautomers or different substitution patterns, which must be separated and characterized carefully.

Research Methodologies for Heterocyclic Carboxamides

The success of tetrazole and triazole carboxamide scaffolds in anticancer drug discovery is increasingly dependent on the integration of advanced research methodologies, moving beyond classical wet-lab synthesis and two-dimensional SAR. This section outlines the key techniques used for efficient discovery and mechanistic validation.

a. High-Throughput Screening (HTS) and Combinatorial Chemistry

The synthetic efficiency of Click Chemistry for triazoles makes these scaffolds perfectly suited for High-Throughput Screening (HTS) campaigns [15].

- **Combinatorial Library Synthesis:** CuAAC allows for the rapid, parallel synthesis of diverse triazole-carboxamide libraries by systematically varying the alkyne and azide precursors. These large libraries are then screened against multiple targets (e.g., kinase panels, cell proliferation assays) simultaneously, significantly accelerating the hit identification phase [16].

- **Target Agnostic Screening:** HTS is essential for discovering novel mechanisms, as it can identify compounds with high cellular toxicity (GI_{50} or IC_{50}) whose primary molecular target is yet unknown.

b. Computational Modeling and Drug Design

In silico methodologies are crucial for rationalizing observed activity and guiding the synthesis of new, optimized compounds. They help reduce the time and cost associated with empirical synthesis.

- **Molecular Docking:** This is routinely used to predict the preferred binding orientation and affinity of a

carboxamide derivative within the active site of a target protein (e.g., EGFR kinase or HDAC). It offers visual insights into the specific H-bonding and hydrophobic interactions mediated by the carboxamide, tetrazole, and triazole rings [17].

- **3D-QSAR Modeling:** Advanced Quantitative Structure-Activity Relationship models help establish mathematical correlations between the electronic, steric, and physicochemical properties of the scaffolds and their measured biological activity (IC_{50}). This allows researchers to accurately predict the potency of *untested* derivatives and optimize substituents before committing to synthesis, drastically streamlining the SAR process.

- **Molecular Dynamics (MD) Simulations:** MD is critical for understanding the flexibility and stability of the drug-target complex over time. It can reveal how the flexible carboxamide linker moves and adapts within the pocket, and how the stability of the triazole or tetrazole ring contributes to the overall binding kinetics.

c. Mechanistic and Phenotypic Profiling

Once a potent compound is identified, advanced methods are needed to confirm its precise mechanism of action and its effects on the cancerous phenotype.

- **Cell Cycle Analysis:** Flow cytometry is frequently used to determine if the hybrids cause cell death via apoptosis or lead to cell cycle arrest (e.g. G2/M arrest, common for tubulin inhibitors) [18].

- **Target Deconvolution:** Techniques like Affinity Chromatography or Cellular Thermal Shift Assays (CETSA) are employed to confirm the direct molecular target of the compound within a living cell, providing robust validation for claimed kinase or HDAC inhibition.

- **Off-Target Selectivity Screening:** Comprehensive selectivity panels (e.g., against a library of 400+ human kinases) are essential to demonstrate that the compound is selective for the intended target, addressing the major challenge of off-target toxicity [2].

Discussion

This section synthesizes the key findings from the tetrazole and triazole carboxamide scaffolds, discusses the primary hurdles to their successful translation into clinical anticancer drugs, and proposes specific research avenues for the future.

a. Key Challenges in Drug Development

Despite the high potency demonstrated by many heterocyclic carboxamide hybrids in preclinical studies, several challenges must be addressed for successful drug development:

1. Bioavailability and Physicochemical Properties

- **Tetrazoles:** While acting as a COOH bioisostere, the high polarity and increased acidity of the tetrazole ring can negatively impact membrane permeability and oral absorption [9]. Achieving the necessary balance between water solubility (for formulation) and lipophilicity (for cell penetration) remains a significant design challenge.
- **Carboxamides:** The amide bond, though metabolically stable, possesses a high capacity for H-bonding, which can sometimes push the compound outside the ideal range for drug-likeness, potentially leading to poor permeability across biological membranes [19].

2. Toxicity and Off-Target Effects

- **Off-Target Selectivity:** Many potent kinase and Topoisomerase inhibitors can interact with structurally similar enzymes or non-specific cellular components, leading to unwanted side effects [2]. Detailed selectivity panels and high-throughput screening are necessary to ensure the observed anticancer effect is not due to general toxicity, especially given the shared binding features of many nitrogen heterocycles.

- **Metabolic Stability:** The carboxamide is generally stable, but the attached rings can be targets for metabolic enzymes, potentially leading to rapid clearance or the formation of toxic metabolites.

3. Synthesis Scaling: Although Click Chemistry is highly efficient for triazoles, scaling up the synthesis of certain tetrazoles that require hazardous azide reagents or specific high-pressure conditions remains a logistical and cost challenge.

b. Most Promising Scaffold-Target Combinations

Based on the potent SAR and mechanistic data, the following combinations represent the most promising directions for future drug development:

1. **Tetrazole Carboxamides as Kinase Inhibitors (VEGFR-2/PDGFR):** This is a highly successful pairing where the tetrazole effectively mimics a carboxylic acid or a key H-bond acceptor within the ATP-binding pocket. Compounds in this class often show sub-micromolar potency and represent excellent starting points for developing oral, targeted therapeutics [11].

2. **Triazole Carboxamides as HDAC Inhibitors:** The rigid and metabolically stable 1,2,3 triazole moiety serves as an ideal rigid linker connecting the surface-binding cap and the zinc-chelating group [16]. This provides the structural precision necessary for selective HDAC isoform inhibition, a critical strategy in epigenetic cancer therapy.

3. **Triazole Carboxamides as Tubulin Polymerization Inhibitors:** Due to the versatility of Click Chemistry, large libraries of triazole hybrids have been generated, leading to highly potent agents that effectively disrupt the microtubule dynamics. These compounds, with their novel structural features, offer a potential path to overcome resistance to current tubulin-targeting drugs like taxanes [18].

c. Future Perspectives and Rational Design

To overcome the inherent challenges and maximize the therapeutic potential of these scaffolds, future research should prioritize two main directions:

1. **Exploiting Computational Methods:** Advanced computational techniques, such as Molecular Dynamics (MD) simulations and 3D-QSAR (Quantitative

Structure-Activity Relationship) modeling, will be essential. These tools can provide deeper mechanistic insights by:

- Accurately predicting binding affinities and selectivity profiles, moving beyond simple SAR to rational drug design.
- Modeling the dynamic behavior of the ligand-target complex to understand how the flexible carboxamide and rigid heterocycles achieve their optimal binding conformation.

2. **Addressing Drug Resistance and Selectivity:** A key future focus must be the design of dual-acting or multi-target agents. For example, creating a single molecule that combines the kinase-inhibiting properties of a tetrazole carboxamide with the apoptosis-inducing activity of a triazole hybrid. Furthermore, designing prodrugs where the active carboxamide or tetrazole moiety is temporarily masked can potentially improve oral bioavailability and reduce systemic toxicity, only releasing the active drug upon reaching the tumor site.

Conclusion and Future Outlook

The current landscape of anticancer drug discovery strongly affirms the pivotal role of heterocyclic carboxamide scaffolds, particularly those incorporating the 1H-tetrazole and 1,2,3-triazole motifs. Our comprehensive analysis demonstrates that these scaffolds are not merely random appendages but essential architectural elements that dictate crucial interactions and physicochemical properties [1].

1. Integration of Scaffolds and Pharmacophores

The carboxamide group provides the necessary hydrogen-bonding foundation and conformational flexibility required for precise engagement with target active sites, notably in kinase inhibitors and agents targeting DNA topology [7]. The nitrogen heterocycles act as molecular translators:

- The tetrazole ring excels as an acid bioisostere, often coordinating with critical residues or metal ions in targets like VEGFR-2, yielding compounds with high potency [11].
- The triazole ring, thanks to its synthesis via Click Chemistry, serves as a robust, non-hydrolyzable linker that optimally rigidifies the molecule for targets like HDACs and tubulin, enhancing specificity and metabolic stability [16, 18].

These combined roles highlight a rational design strategy: the heterocycle defines the core functionality (acid mimicry or rigid linking), while the carboxamide ensures the necessary binding affinity and orientation.

2. Moving Beyond Preclinical Success: The Road to the Clinic

Translating these potent preclinical hits into clinically viable drugs requires a concerted effort to mitigate the inherent challenges discussed, particularly poor bioavailability and off-target toxicity [2]. The next generation of research must move past empirical SAR and embrace fully integrated approaches:

a. **Harnessing Computational Power**: 3D-QSAR models and Molecular Dynamics simulations are no longer auxiliary tools but core necessities. These techniques must be used proactively to predict and fine-tune solubility, permeability, and metabolic hotspots *before* synthesis, thereby steering research toward compounds that comply with Lipinski's rules and possess favorable pharmacokinetic profiles [19].

b. **Strategic Prodrug Design:** To overcome issues like poor oral absorption stemming from the polarity of the tetrazole ring, future studies should investigate prodrug strategies. Temporarily masking the polar moieties could enhance membrane permeability, allowing the active drug to be released selectively by enzymatic cleavage within the tumor microenvironment.

c. **Resistance and Multi-Targeting:** The increasing prevalence of drug resistance demands the design of novel molecules capable of multi-target inhibition or those active against resistant tumor lines. The synthetic flexibility offered by CuAAC is perfect for rapidly creating hybrid molecules that simultaneously hit two distinct targets (e.g., a kinase and an HDAC to achieve synergistic therapeutic effects and preempt resistance mechanisms.

In essence, the future of these scaffolds lies in leveraging synthetic flexibility (especially Click Chemistry) and computational predictability to ensure that the exquisite biological potency observed in the lab is matched by favorable pharmacological properties suitable for patient treatment.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2024. CA: A Cancer Journal for Clinicians,2024:74(1):7–34.
2. Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature,2019:575(7782):299–309.
3. Sani MM, Danladi JA, Attayee JM. A review on anticancer drug design and development. European Journal of Medicinal Chemistry,2021:222:113612.
4. Li J, Liu B, Zhang Y. Heterocyclic compounds: an overview of their synthetic and medicinal applications. Chemical Reviews,2020:120(15):7247–7328.
5. Al-Warhi TI, El-Sayed O. The strategic importance of nitrogen heterocycles in current medicinal chemistry. Medicinal Chemistry Research,2022:31:1547–1567.
6. Sharma PK, Kumar R. Carboxamide-containing compounds: A privileged scaffold in therapeutic interventions. Mini-Reviews in Medicinal Chemistry,2023:23(10):990–1004.
7. Settle AB, Zhang C. Targeted inhibition of protein kinases with a focus on BCR-ABL: The role of the carboxamide group. ACS Medicinal Chemistry Letters,2018:9(8):754–759.
8. Keri RS, Suresh S, Shivananda MK. Tetrazole and triazole derivatives as promising anti-cancer agents. European Journal of Medicinal Chemistry,2020:207:11 2839.
9. Ballell L, Fecik RA. The tetrazole as a carboxylic acid bioisostere: A key motif in drug design. Chemical Communications,2019:55(55):7859–7867.
10. Gadi VK, Smith JR. Click chemistry-derived 1,2,3-triazole conjugates in cancer therapy: Synthesis and biological activity. Bioorganic, Medicinal Chemistry,2022:60:116664.
11. Jia L, *et al*. Discovery of novel N-aryl tetrazole carboxamides as potent VEGFR-2 inhibitors with

enhanced oral bioavailability. Journal of Medicinal Chemistry,2023:66(14):10001–10015.
12. Zhang Y, *et al*. Design, synthesis and biological evaluation of new tetrazole-carboxamide derivatives as potential Topoisomerase I inhibitors. RSC Advances,2021:11(40):24699–24707.
13. Ali HR, *et al*. Synthesis of novel tetrazole-carboxamide derivatives as potent dual COX-2/LOX inhibitors with promising anticancer activity. European Journal of Medicinal Chemistry,2020:198:112345.
14. Kim MJ, *et al*. Tetrazole-based hybrids targeting tubulin polymerization: SAR and *in vitro* evaluation. Bioorganic, Medicinal Chemistry Letters,2022:36:128790.
15. Kolb HC, Finn MG, Sharpless KB. Click chemistry: diverse chemical function from a few good reactions. Angewandte Chemie International Edition,2001:40(11):2004–2021.
16. Musa MA, *et al*. Design, synthesis and HDAC inhibition of novel triazole-carboxamide hydroxamate derivatives. Journal of Medicinal and Pharmaceutical Chemistry Research,2023:4(1):123–135.
17. Wang F, *et al*. Highly efficient synthesis of novel triazole-carboxamide hybrids via click chemistry as potent EGFR inhibitors. European Journal of Medicinal Chemistry,2022:239:114532.
18. Zhou L, *et al*. Triazole-carboxamide hybrids as a novel class of tubulin polymerization inhibitors: design, synthesis, and SAR study. ACS Medicinal Chemistry Letters,2021:12(8):1289–1295.
19. Lipinski CA. Lead- and drug-like compounds: the rule-of-five revolution. Drug Discovery Today: Technologies,2004:1(4):337–341.